A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

Pece, Alfredo; Milani, Paolo; Monteleone, Carla; Trombetta, C. J.; Crecchio, Giuseppe de; Fasolino, Giuseppe; Matranga, Domenica; Cillino, Salvatore; Vadalà, Maria

doi:10.1007/s00417-014-2886-x

Cited by 21 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite these limitations, our study supports the current data available regarding the long-term effectiveness of anti-VEGF therapies in patients with mCNV. Several studies on the treatment of mCNV with ranibizumab report good visual outcomes over more than 12 months of follow-up, 18 , 20 – 26 , 29 , 30 but most follow preestablished treatment protocols. A Portuguese case series on 39 eyes reported a mean BCVA gain of 8.0 ETDRS letters after 3 years of follow-up with 35% of patients gaining ≥15 letters after this time period.…”

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization in East-Asian Patients From the Radiance Study

Tan

Ohno‐Matsui

Koh

et al. 2018

Retina

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization in East-Asian Patients From the Radiance Study

Tan

Ohno‐Matsui

Koh

et al. 2018

Retina

View full text Add to dashboard Cite

show abstract

“…However, in our study, NV in eyes with concomitant AMD and HM showed a different clinical course and response to treatment compared to NV associated with typical AMD, as previously reported in the literature. 33,34 In our population, more anti-VEGF intravitreal injections were needed to restore functional and anatomic parameters than that reported in the purely myopic population [35][36][37][38] (3.8 injections in our AMD/myopia population versus 1.8-3.6 injections in the purely myopic population using a PRN protocol in the first year of treatment). [28][29][30][31] However, 3.8 represents a reduced number of injections needed to optimally treat NV in AMD (4.3-6.9 injections in the first year of PRN treatment has been reported).…”

Section: Discussionmentioning

confidence: 78%

Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes With High Myopia

Corbelli

Parravano

Sacconi

et al. 2019

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

PURPOSE. To analyze the frequency and phenotypic variation of AMD in subjects with high myopia (HM), and to describe the clinical course and response to treatment of neovascularization (NV). METHODS. Patients with HM were identified at five retina tertiary referral centers. Inclusion criteria were myopic patients aged 55 years or more with axial lengths equal or greater than 25.5 mm. RESULTS. A total of 874 eyes from 442 HM subjects older than 55 years were identified and 104 eyes of 54 patients (72 6 11 years) were included in the study and followed up for 23.5 6 19.5 months. The estimated AMD frequency in HM subjects over 55 years was 11.9% (95% confidence interval; 9.8%-14.0%). A total of 34 of 104 eyes were diagnosed with drusen, 22 with reticular pseudodrusen (RPD), 28 with both drusen and RPD, and 20 with geographic atrophy. Neovascularization was detected in 52 eyes (50%), and type 1 was the most frequent form (39 eyes, 75%). Overall, NV was treated with 4.6 6 2.6 anti-VEGF injections. Eyes with treatment-naïve NV at baseline (n ¼ 34) required 3.8 6 1.5 anti-VEGF injections during the first year of treatment. This exceeded the injection number in the purely myopic population (1.8 to 3.6 injections for the first year). CONCLUSIONS. This study provides evidence to suggest that older patients with HM are at a significant risk of the dry and neovascular forms of AMD. NV in eyes with HM and AMD required more injections in the first year compared to NV in HM eyes without AMD.

show abstract

“…Similar data were found in the study by Cohen et al [25] with a mean intravitreal ranibizumab number of 3.5 (range 1–12) over a mean follow-up of 39.3 months. Pece et al [38] reported 2.3 intravitreal injections in the ranibizumab subgroup during 20-month follow-up; similarly, Iacono et al [16] reported a mean of 2.5 intravitreal ranibizumab injections over 18 months. A 6-year analysis by Ruiz-Moreno et al [22] revealed a mean of 3.3 injections, and in the longest study of ranibizumab monotherapy for mCNV, Hefner and Gerding [31] performed a mean of 3.5 injections (range 1–12) during a mean follow-up of 85 months.…”

Section: Discussionmentioning

confidence: 99%

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia

et al. 2017

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the 9-year outcome of ranibizumab monotherapy for myopic choroidal neovascularization (mCNV). Methods: This was a retrospective, nonrandomized, multicentric study to evaluate the long-term outcomes of mCNV treated with ranibizumab monotherapy for at least 9 years according to a strict pro re nata regimen. Results: Seventeen eyes of 17 patients (12 women, mean age 57.9 ± 7.7 years) were included. The mean follow-up period was 112.4 ± 3.9 months (range 108–120). The mean difference in best-corrected visual acuity (BCVA) from baseline to the last follow-up was +1.2 ± 15.6 ETDRS letters (p = 0.004, between initial vs. 12 and 24 months). The mean total number of intravitreal injections for each patient was 1.24 ± 1.70 per year (range 2–25). No systemic adverse reactions related to the drug treatment were detected during the 9-year follow-up period. Conclusions: Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.

show abstract

A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV

Abstract: Myopic CNV equally benefits from on-demand intravitreal injection of either bevacizumab or ranibizumab; the therapeutic effect is independent of previous PDT and age.

Cited by 21 publications

References 32 publications

Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization in East-Asian Patients From the Radiance Study

Long-Term Outcomes of Ranibizumab Treatment of Myopic Choroidal Neovascularization in East-Asian Patients From the Radiance Study

Prevalence and Phenotypes of Age-Related Macular Degeneration in Eyes With High Myopia

Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia

Contact Info

Product

Resources

About